{
    "nct_id": "NCT04499924",
    "official_title": "A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC)\n* HER2+ disease documented since progression of the most recent line of systemic therapy, as follows:\n\n  * Phase 2 paclitaxel dose optimization stage:\n\n    * HER2 amplification in a blood-based NGS assay performed at a central laboratory, or\n    * HER2 overexpression/amplification immunohistochemistry (IHC) and in situ hybridization (ISH) (IHC3+ or IHC2+/ISH+) assay of a tumor tissue sample\n  * Phase 2 dose expansion stage:\n\n    * Cohort 2A: HER2 amplification in a blood-based NGS assay performed at a central laboratory\n    * Cohort 2B: No HER2 amplification by blood-based NGS assay, but HER2 overexpression/amplification by IHC and ISH (IHC3+ or IHC2+/ISH+) assay of a tumor tissue sample\n  * Phase 3: HER2 amplification in a blood-based NGS assay performed at a central laboratory\n* History of prior treatment with a HER2-directed antibody\n* Progressive disease during or after first-line therapy for locally-advanced unresectable or metastatic GEC\n* Phase 2: Measurable disease according to RECIST version 1.1\n* Phase 3: Measurable or non-measurable disease according to RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Life expectancy of at least 3 months, in the opinion of the investigator\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subjects with squamous cell or undifferentiated GEC\n* Having received more than 1 line of prior systemic therapy for locally-advanced unresectable or metastatic disease\n* Having received taxanes â‰¤12 months prior to enrollment, prior treatment with ramucirumab, or prior treatment with tucatinib, lapatinib, neratinib, afatinib, or any other investigational anti-HER2 and/or anti-EGFR tyrosine kinase inhibitor, or with T-DM1, T-Dxd, or any other HER2-directed antibody-drug conjugate\n* Phase 2 paclitaxel dose optimization stage only: history of prior partial or total gastrectomy\n* Unable to swallow pills",
    "miscellaneous_criteria": ""
}